Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis (TREM-1)
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Verwacht)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Metz, Frankrijk
- Werving
- Centre Hospitalier de Metz Thionville
-
Contact:
- Claire Gamelon - Benichou, MD
-
Nancy, Frankrijk
- Werving
- Institut de Cancérologie de Lorraine
-
-
-
-
SUD
-
Esch-sur-Alzette, SUD, Luxemburg, 4240
- Werving
- Centre François Baclesse
-
Contact:
- Guillaume Vogin, MD PhD
-
Contact:
- Charlotte Lieunard
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Group A
- Patients over 18 years old,
- Breast cancer (adenocarcinoma in situ or invasive)
- Non-metastatic disease
- Radiotherapy after conservative surgery with irradiation of the breast alone and complement on the operating bed (optional) completed two to six months ago
- Absence of postoperative complications
- Early radio-induced epidermis grade ≥2 (CTCAE v4.0) persistent at inclusion
- Chest circumference <120 cm and Cup <E,
- Absence of breast reconstructive surgery,
- Signature of informed consent,
- Affiliation to a social security scheme for French patients.
Group B
- Patients over 18 years old,
- Breast cancer (adenocarcinoma in situ or invasive)
- Non-metastatic disease
- Radiotherapy after conservative surgery with irradiation of the breast alone and complement on the operating bed (optional), completed two to six months ago
- Absence of postoperative complications
- Early grade 0-1 radiation-induced epidermis (CTCAE v4.0) at inclusion
- Chest circumference <120 cm and Cup <E,
- Absence of breast reconstructive surgery,
- Signature of informed consent,
- Affiliation to a social security scheme for French patients.
Groups C, D
Patients included in the SPLICIRAD study who have formulated their agreement for the use of supernumerary samples at the time of inclusion:
- 10 patients with late pathologic radio-induced fibrosis (more than 6 months after the end of radiotherapy), grade CTCAE v4.0 ≥ 3 vs.
- 10 patients without late pathological radio-induced fibrosis of grade CTCAE v4.0 ≤ 1 (follow-up after RT ≥4 years)
Group E Patients over 18 who have given their consent to the Blood Establishment for the use of their samples for research purposes.
Non-inclusion criteria for groups A, B, C, D:
- Systemic inflammatory disease associated with individual radiosensitivity
- Dermatological pathology in the breast
- Radiotherapy having delivered an overdose> 107% of the prescribed dose in at least 10% of the PTV
- Diabetes
- Active smoking
- Chronic systemic anti-inflammatory therapy, immunotherapy, immunosuppressants, anti-TNF
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Ander: Group A
Patients with early grade ≥2 radio-induced epidermis Intervention : blood sample
|
Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
|
|
Ander: Group B
Patients with early grade 0-1 radiation-induced epidermis Intervention : blood sample
|
Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
|
|
Geen tussenkomst: Group C
Patients with late pathologic radio-induced fibrosis (more than 6 months after the end of radiotherapy), grade CTCAE v4.0 ≥ 3 No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
|
|
|
Geen tussenkomst: Group D
Patients without late pathologic radio-induced fibrosis of grade CTCAE v4.0 ≤ 1 (follow-up after RT ≥4 years) No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
|
|
|
Geen tussenkomst: Group E
Control group : patients over 18 who have given their consent to the Blood Establishment for the use of their samples for research purposes.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Coorelate the amount of circulating TREM1 with the presence or absence of early persistent radiation-induced epidermis.
Tijdsspanne: after recruitment of all samples, an average of 2 years
|
Correlate the amount of circulating TREM1 with the presence or absence of early persistent radiation-induced epidermis.
|
after recruitment of all samples, an average of 2 years
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Correlate the amount of circulating TREM1 with the presence or absence of late radio-induced fibrosis / atrophy
Tijdsspanne: after recruitment of all samples, an average of 2 years
|
Correlate the amount of circulating TREM1 with the presence or absence of late radio-induced fibrosis / atrophy
|
after recruitment of all samples, an average of 2 years
|
|
Intrinsic characteristics of the TREM1 blood assay in ELISA technique
Tijdsspanne: after recruitment of all samples, an average of 2 years
|
Intrinsic characteristics of the TREM1 blood assay in ELISA technique
|
after recruitment of all samples, an average of 2 years
|
|
correlate TREM-1 expression with circulating markers of inflammation such as IL-6, CRP, and fibrosis such as TGF-beta, IL-1beta, TNF-alpha
Tijdsspanne: after recruitment of all samples, an average of 2 years
|
correlate TREM-1 expression with circulating markers of inflammation such as IL-6, CRP, and fibrosis such as TGF-beta, IL-1beta, TNF-alpha
|
after recruitment of all samples, an average of 2 years
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Verwacht)
Primaire voltooiing
Studie voltooiing (Verwacht)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- TREM-1
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .